Cargando…

TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma

PURPOSE: To investigate the effectiveness and safety of transarterial chemoembolization (TACE) combined with sorafenib and thermal ablation in patients with huge hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This retrospective study examined 50 patients with huge unresectable HCC treated fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Ying, Qi, Han, Cao, Fei, Shen, Lujun, Chen, Shuanggang, Xie, Lin, Huang, Tao, Song, Ze, Zhou, Danyang, Fan, Weijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438914/
https://www.ncbi.nlm.nih.gov/pubmed/32903854
http://dx.doi.org/10.3389/fphar.2020.01130
_version_ 1783572889256067072
author Wu, Ying
Qi, Han
Cao, Fei
Shen, Lujun
Chen, Shuanggang
Xie, Lin
Huang, Tao
Song, Ze
Zhou, Danyang
Fan, Weijun
author_facet Wu, Ying
Qi, Han
Cao, Fei
Shen, Lujun
Chen, Shuanggang
Xie, Lin
Huang, Tao
Song, Ze
Zhou, Danyang
Fan, Weijun
author_sort Wu, Ying
collection PubMed
description PURPOSE: To investigate the effectiveness and safety of transarterial chemoembolization (TACE) combined with sorafenib and thermal ablation in patients with huge hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This retrospective study examined 50 patients with huge unresectable HCC treated from January 2009 to December 2015. Among them, 28 cases received TACE-sorafenib treatment (TACE-sorafenib group), and 22 cases received TACE-sorafenib plus thermal ablation treatment (TACE-sorafenib-thermal ablation group). The Overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were compared. RESULTS: The median follow-up was 13.5 months (ranges 4.2 to 96.7 months). The median OS was significantly longer in the TACE-sorafenib-thermal ablation group than that in the TACE-sorafenib group (20.8 vs. 10.4 months, P=0.003). The median PFS of the ablation and no ablation groups were 4.3 vs. 7.1 months (P=0.546). The treatment modality was an independent predictor of OS (P=0.004). There were no notable drug-related high grade adverse events or permanent adverse sequelae. CONCLUSION: TACE-sorafenib-thermal ablation provided extended OS to patients with huge unresectable HCC and could be a better choice than TACE-sorafenib.
format Online
Article
Text
id pubmed-7438914
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74389142020-09-03 TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma Wu, Ying Qi, Han Cao, Fei Shen, Lujun Chen, Shuanggang Xie, Lin Huang, Tao Song, Ze Zhou, Danyang Fan, Weijun Front Pharmacol Pharmacology PURPOSE: To investigate the effectiveness and safety of transarterial chemoembolization (TACE) combined with sorafenib and thermal ablation in patients with huge hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This retrospective study examined 50 patients with huge unresectable HCC treated from January 2009 to December 2015. Among them, 28 cases received TACE-sorafenib treatment (TACE-sorafenib group), and 22 cases received TACE-sorafenib plus thermal ablation treatment (TACE-sorafenib-thermal ablation group). The Overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were compared. RESULTS: The median follow-up was 13.5 months (ranges 4.2 to 96.7 months). The median OS was significantly longer in the TACE-sorafenib-thermal ablation group than that in the TACE-sorafenib group (20.8 vs. 10.4 months, P=0.003). The median PFS of the ablation and no ablation groups were 4.3 vs. 7.1 months (P=0.546). The treatment modality was an independent predictor of OS (P=0.004). There were no notable drug-related high grade adverse events or permanent adverse sequelae. CONCLUSION: TACE-sorafenib-thermal ablation provided extended OS to patients with huge unresectable HCC and could be a better choice than TACE-sorafenib. Frontiers Media S.A. 2020-07-29 /pmc/articles/PMC7438914/ /pubmed/32903854 http://dx.doi.org/10.3389/fphar.2020.01130 Text en Copyright © 2020 Wu, Qi, Cao, Shen, Chen, Xie, Huang, Song, Zhou and Fan http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wu, Ying
Qi, Han
Cao, Fei
Shen, Lujun
Chen, Shuanggang
Xie, Lin
Huang, Tao
Song, Ze
Zhou, Danyang
Fan, Weijun
TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma
title TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma
title_full TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma
title_fullStr TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma
title_full_unstemmed TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma
title_short TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma
title_sort tace-sorafenib with thermal ablation has survival benefits in patients with huge unresectable hepatocellular carcinoma
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438914/
https://www.ncbi.nlm.nih.gov/pubmed/32903854
http://dx.doi.org/10.3389/fphar.2020.01130
work_keys_str_mv AT wuying tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma
AT qihan tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma
AT caofei tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma
AT shenlujun tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma
AT chenshuanggang tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma
AT xielin tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma
AT huangtao tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma
AT songze tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma
AT zhoudanyang tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma
AT fanweijun tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma